4.3 Article

Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-Release Tablets to Elderly and Young Subjects

Journal

DRUGS & AGING
Volume 32, Issue 12, Pages 1029-1043

Publisher

ADIS INT LTD
DOI: 10.1007/s40266-015-0315-4

Keywords

-

Funding

  1. Labopharm

Ask authors/readers for more resources

Background Tramadol is frequently used in geriatric patients; however, pharmacokinetic (PK) publications on tramadol and O-desmethyltramadol (ODM) in elderly patients are rare. Objective Our objective was to characterize the PK of tramadol and ODM, including absorption processes and covariates for tramadol, in elderly and young subjects after single-dose administration of 200-mg extended-release tablets. Methods We conducted a PK study in 15 elderly (aged >= 75 years) subjects with mild renal insufficiency and 20 young (18-40 years) subjects; blood and urine samples were collected for 48 h post-dose. Non-compartmental analysis (NCA) of each tramadol and ODM enantiomer included area under the concentration-time curve (AUC), terminal elimination rate (k(el)), total body clearance, volume of distribution (V-area/F), and renal clearance (Clr(0-48)). A one-compartment population model of total tramadol concentration was parameterized with clearance (CL/F), volume of distribution (V/F), and mixed order absorption (first-order and zero-order absorption rate constants with lag times). Results NCA demonstrated comparable maximum plasma concentration (C-max) and AUC between age groups for tramadol enantiomers, but significant differences in V-area/F (mean 34 % higher) and kel (mean 28 % lower) in the elderly. PK of ODM were significantly different in the elderly for AUC(0-inf) (mean 35 % higher), Clr(0-48) (mean 29 % lower), and kel (mean 33 % lower). The population analysis identified age as a covariate of V/F (young 305 L; elderly 426 L), with a 50 % longer mean elimination half-life in the elderly. No differences in absorption processes were observed. Conclusions Tramadol exposure was similar between the age groups; exposure to ODM was higher in elderly subjects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

Daniele Ouellet, Nastya Kassir, Joannellyn Chiu, Mohamad-Samer Mouksassi, Cathrine Leonowens, Donna Cox, Douglas J. DeMarini, Olivia Gardner, Wendy Crist, Kiran Patel

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)

Article Geriatrics & Gerontology

Population Pharmacokinetic/Pharmacodynamic Modeling of O-Desmethyltramadol in Young and Elderly Healthy Volunteers

Sybil Skinner Robertson, Mohamad Samer Mouksassi, France Varin

DRUGS & AGING (2019)

Article Public, Environmental & Occupational Health

Power calculations for cluster randomized trials (CRTs) with right-truncated Poisson-distributed outcomes: a motivating example from a malaria vector control trial

Lazaro M. Mwandigha, Keith J. Fraser, Amy Racine-Poon, Mohamad-Samer Mouksassi, Azra C. Ghani

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2020)

Review Pharmacology & Pharmacy

Model-informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection

Michael Dodds, Yuan Xiong, Samer Mouksassi, Carl M. Kirkpatrick, Katrina Hui, Eileen Doyle, Kashyap Patel, Eugene Cox, David Wesche, Fran Brown, Craig R. Rayner

Summary: This article discusses the five steps of model-informed drug repurposing (MIDR) and categorizes activities under these steps into three stages. MIDR helps extract more information from emerging data and integrate disparate data into actionable insights.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Article Anesthesiology

Peak plasma concentration of total and free bupivacaine after erector spinae plane and pectointercostal fascial plane blocks

Sarah Maximos, Eric Vaillancourt-Jean, Samer Mouksassi, Alessandro De Cassai, Sophie Ayoub, Monique Ruel, Julie Desroches, Pierre-Oliver Hetu, Alex Moore, Stephan Williams

Summary: The aim of this study was to investigate the maximum concentrations and timing of plasma bupivacaine after ESPB and PIFB. The study found that the C-max of total and free bupivacaine were significantly lower than toxic levels reported in the literature when using a dose of 2 mg/kg.

CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE (2022)

Article Pharmacology & Pharmacy

Evaluation of covariate effects using forest plots and introduction to the coveffectsplot R package

Jean-Francois Marier, Nathan Teuscher, Mohamad-Samer Mouksassi

Summary: This tutorial explains the importance of forest plots in communicating covariate effects effectively, the construction methods, and presentation techniques. It also introduces simulation-based methodologies and graphical tools for evaluating covariate effects, along with providing an R package and application for designing and constructing forest plots.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2022)

Article Medicine, Research & Experimental

Totality of evidence of the effectiveness of repurposed therapies for COVID-19: Can we use real-world studies alongside randomized controlled trials?

Jaap Mandema, Hugh Montgomery, Louis Dron, Shuai Fu, Estelle Russek-Cohen, Christina Bromley, Samer Mouksassi, Amy Lalonde, Aaron Springford, Larry Tsai, Phil Ambery, Doug Mcnair, Nawab Qizilbash, Stuart Pocock, Nevine Zariffa

Summary: Rapid and robust strategies that include large randomized controlled trials (RCTs) and well-designed observational real-world studies (RWS) are necessary to evaluate the efficacy and effectiveness of pharmacotherapeutic interventions in future pandemics. The results of a study analyzing the data from COVID-19 RCTs and RWS suggest that large RCTs provide more accurate conclusions about the clinical benefits of treatments, while RWS tend to yield more varied results. Therefore, in future pandemics, prioritizing large RCTs, improving the design and data matching of RWS, enhancing reporting standards, and promoting access to patient-level data are crucial for evaluating therapies.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2023)

Article Anesthesiology

Evaluation of an Experimental Pain Model by Noncompartmental Analysis of Results from a Randomized Placebo Controlled Trial

Sybil Skinner-Robertson, Mohamad-Samer Mouksassi, France Varin

PAIN PHYSICIAN (2018)

Article Urology & Nephrology

Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease

Ronald D. Perrone, Mohamad-Samer Mouksassi, Klaus Romero, Frank S. Czerwiec, Arlene B. Chapman, Berenice Y. Gitomer, Vicente E. Torres, Dana C. Miskulin, Steve Broadbent, Jean F. Marier

KIDNEY INTERNATIONAL REPORTS (2017)

Article Urology & Nephrology

A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease

Ronald D. Perrone, Mohamad-Samer Mouksassi, Klaus Romero, Frank S. Czerwiec, Arlene B. Chapman, Berenice Y. Gitomer, Vicente E. Torres, Dana C. Miskulin, Steve Broadbent, Jean F. Marier

KIDNEY INTERNATIONAL REPORTS (2017)

Article Computer Science, Interdisciplinary Applications

Phxnlme: An R package that facilitates pharmacometric workflow of Phoenix NLME analyses

Chay Ngee Lim, Shuang Liang, Kevin Feng, Jason Chittenden, Ana Henry, Samer Mouksassi, Angela K. Birnbaum

COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2017)

Article Pharmacology & Pharmacy

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

T. H. T. Nguyen, M-S Mouksassi, N. Holford, N. Al-Huniti, I. Freedman, A. C. Hooker, J. John, M. O. Karlsson, D. R. Mould, J. J. Perez Ruixo, E. L. Plan, R. Savic, J. G. C. van Hasselt, B. Weber, C. Zhou, E. Comets, F. Mentre

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)

Article Pharmacology & Pharmacy

Population Pharmacokinetic Modeling of Motesanib and Its Active Metabolite, M4, in Cancer Patients

Nathalie H. Gosselin, Mohamad-Samer Mouksassi, Jian-Feng Lu, Cheng-Pang Hsu

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2015)

Article Pharmacology & Pharmacy

Population Pharmacokinetic Analysis of Thrombomodulin Alfa to Support Dosing Rationale in Patients with Renal Impairment

Mohamad-Samer Mouksassi, Jean-Francois Marier, Leon Bax, Yutaka Osawa, Kazuhisa Tsuruta

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2015)

No Data Available